Engineering nanoparticle surface chemistry for antigen-presenting cell targeting improves specificity and safety of TLR3 agonist cancer immunotherapy
This study demonstrates that engineering a dextran sulfate-coated nanoparticle platform to specifically target antigen-presenting cells significantly enhances the safety, therapeutic window, and anti-tumor efficacy of the TLR3 agonist poly(I:C) in a metastatic ovarian cancer model by reducing systemic toxicity and improving tumor delivery.